CIK 0001651308
- Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981209416
- Phone
- +41 616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-06-05 | Liang Howard CFO & Chief Strategy Officer | Grant or award · Share Option (Right to Buy) | +558,285 | 558,285 | ||
| 2019-06-05 | Chen Timothy Yung-Cheng Director | Grant or award · Share Option (Right to Buy) | +64,610 | 64,610 | ||
| 2019-06-05 | Wu Xiaobin President & GM China | Grant or award | +433,472 | 1,505,956 | ||
| 2019-06-05 | Wu Xiaobin President & GM China | Grant or award · Share Option (Right to Buy) | +797,550 | 797,550 | ||
| 2019-06-05 | su Jingshyh S Director | Grant or award · Share Option (Right to Buy) | +64,610 | 64,610 | ||
| 2019-06-05 | Glazer Donald W. Director | Grant or award · Share Option (Right to Buy) | +64,610 | 64,610 | ||
| 2019-06-05 | Malley Thomas Director | Grant or award · Share Option (Right to Buy) | +64,610 | 64,610 | ||
| 2019-06-05 | OYLER JOHN Chief Executive Officer | Grant or award · Share Option (Right to Buy) | +2,193,282 | 2,193,282 | ||
| 2019-06-05 | BAKER BROS. ADVISORS LP Director | Grant or award · Shares Option (Right to Buy) | +129,220 | 129,220 | ||
| 2019-05-21 | Huang Jane CMO, Hematology | Exercise or conversion | +2,200 | $45.31 | $100K | 2,200 |
| 2019-05-21 | Huang Jane CMO, Hematology | Sale | −2,200 | $130.06 | $286K | 0 |
| 2019-05-21 | Huang Jane CMO, Hematology | Exercise or conversion · Share Option (Right to Buy) | +28,600 | 947,965 | ||
| 2019-05-21 | Liang Howard CFO & Chief Strategy Officer | Exercise or conversion | +23,200 | $6.50 | $151K | 23,200 |
| 2019-05-21 | Liang Howard CFO & Chief Strategy Officer | Sale | −23,200 | $130.21 | $3.0M | 0 |
| 2019-05-21 | Liang Howard CFO & Chief Strategy Officer | Exercise or conversion · Share Option (Right to Buy) | +301,600 | 4,120,000 | ||
| 2019-05-20 | Huang Jane CMO, Hematology | Exercise or conversion | +300 | $45.31 | $14K | 300 |
| 2019-05-20 | Huang Jane CMO, Hematology | Sale | −300 | $130.12 | $39K | 0 |
| 2019-05-20 | Huang Jane CMO, Hematology | Exercise or conversion · Share Option (Right to Buy) | +3,900 | 976,565 | ||
| 2019-05-13 | Glazer Donald W. Director | Sale | −15,027 | $125.11 | $1.9M | 0 |
| 2019-05-06 | Liang Howard CFO & Chief Strategy Officer | Exercise or conversion | +1,800 | $6.50 | $12K | 1,800 |
Page 102 of 123 · 2,455 trades